Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its target price lowered by HC Wainwright from $344.00 to $335.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
ASND has been the subject of several other research reports. Raymond James Financial cut Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 target price for the company. in a research report on Tuesday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, October 13th. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Finally, Oppenheimer upped their price target on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. Nineteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $313.52.
Read Our Latest Report on Ascendis Pharma A/S
Ascendis Pharma A/S Price Performance
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.47% and a net margin of 73.26%. The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Sell-side analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.
Insider Buying and Selling
In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.00% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ASND. Allworth Financial LP lifted its position in shares of Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after buying an additional 122 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares during the last quarter. Fifth Third Bancorp boosted its stake in Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 91 shares during the last quarter. Parallel Advisors LLC boosted its stake in Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 148 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in Ascendis Pharma A/S by 3,491.7% during the 2nd quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 419 shares in the last quarter.
Ascendis Pharma A/S News Roundup
Here’s some of the latest news about ASND:
- Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
- Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
- Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Further Reading
- Five stocks we like better than Ascendis Pharma A/S
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
